TCACM1061-2018药物经济学评价报告质量评估指南

ICSC T/CACM1061—Guidelinesforqualityassessmentofpharmacoeconomicsevaluation 中发布T/CACMT/CACM1061—目前 引 概 前GB/T1.1《标准化工作导则第1部分：标准的结构和编写》给出的规则起草。引T/CACMT/CACM1061—药物经济学质量评价价值PEERs525，56（A1，A2，21（B1，B2，52C15，362D3，51E3，822～4 E1-E1-E1-E2-E2-E3-E3-权重ABCDE若无条目“E3-13（完全符合）×6（条目数）“C8-1同货币类型转换为同一年及同一种货币表达的成本”（研究时限超过1年时应在报“E3-1（60%≤报告总分＜75%，报告根据实际情况修改完善后具有一定的参考价值；T/CACMT/CACM1061—30123本效果分析A1-A2-研究背B1-B1-B1-研究目的及意B2-B2-C1-C1-C2-C2-C2-C3-C3-研究人群和亚C4-C4-干预措施及对C5-C5-C6-C6-C7-C7-C8-C8-健康产出指标C9-C9-测量和评估基于偏好的健康C10-C10-资源消耗和成C11-C11-C11-C11-C11-C12-C13-C13-C13-C13-数据处理及分C14-C14-C14-C15-C15-成本与健康产D1-D1-进行“增量成本/增量产D2-D2-D3-E1-E1-E1-E2-E2-E2-说明研究的资金来源和资助者在研究问题确定、研究设说明其他非资金支持者的情E3-E3-说明资助者在研究问题确T/CACMT/CACM1061—BergerML,SmithMD.HealthCareCost,Quality,andOutcomes[R].ISPORBookofTerms,ISPOR,2003.DraugalisJR,BoolrmanJL,LarsonLN,etal.In:CurrentConcepts.Pharmacoeconomics[R].Kalamazoo.Michigan;The1Comrany,1989.J],2011,22222023-J].(4):48-J].中国药物应用与监测,2005,2(1):1-4.[J]2010(24):1978-[J].2009,282)80-[J].2003,14(1)4-J(4):73-吴久鸿,赵绯丽,刘国恩.药物经济学研究的质量评价思考[C].南宁:中国药学会(ChinesePharmaceuticalAssociation).20135J]2007,22(3):463-464.J2010,712)23-J].2004,15(1):28-31.2013J26(17):2308-J循证心血管医学杂志,2014,6(3):252-254.J].价,2014,31(6):381-384.J房,2011,22(22):2019-2022.2012—2014学评价指南(2011J]201510812-5[J].海医药,2015,36(1):14-17.2009—2013J].2015,26(11):1441-2010J房,2013,24(26):2401-2404.[J].药杂志,2015,40(10):2050-2053.2007—2011[J].研究,2013,32(1):39-41.J],2011,22222023-2003—2012[J].药房,2014,25(10):865-869.[J]2006,25(8)458-J].杂志,2007,27(4):531-532.[J].2008,19(11):801-805.C]学会.2011年全国医药学术论坛交流会暨临床药学与药学服务研究进展培训班论文集,2011.[J].2014,28(5):536-541.J]学,2008,3(1):48-56.[J]2006,25(6)245-[J]2006,25(6)245-MaynardA.Economicevaluationtechniquesinhealthcare.ReinventingThewheel？[J].Pharmacoeconomics,1997,11(2):115-118.DrummondMF,StoddartGL,TorranceGW.Methodsfortheeconomice-valuationofhealtheareprogrames[J].Oxford:OxofrdUniversityPress,1987.JohnsonJA,FriesenE.ReassessingtherelevanceofpharmacoeconomicAnalysesinformularydecisions[J].Pharmacoeconomics,1998,13(5Pt1):479-485.GendusoLA,KotsanosJG.Reviewofhealtheconomicguidelinesintheformofregulations,principles,policiesandpositions[J].DrugInfJ,1996,(30):l003-l016.[J].药,2006,4(4):16-19.[J].200221(6)21-J].2001,12(3):138-140.[M].DrummondMF,JeffersonTO.GuidelineforauthorandpeerreviewersofeconomicsubmissiontotheBMJ.TheBMJEconomicEvaluationWorkingParty[J].BMJ,1996,313(7052):275-283.D].J卫生经济,2014,33(9):62-65.HusereauD,DrummondM,PetrouS,etal.Consol⁃idatedhealtheconomicevaluationreportingstan⁃dards(CHEERS)-explanationandelaboration:areportoftheISPORhealtheconomicevaluationpublicationguidelinesgoodreportingpracticestaskforce[J].Valuehealth,2013,16(2):231-250.ChiouCF,HayJW,WallaceJF,etal.Developmentandvalidationofagradingsystemforthequalityofcost-effec⁃tivenessstudies[J].MedCare,2003,41(1):32-OfmanJJ,SullivanSD,NeumannPJ,etal.Exam⁃iningthevalueandqualityofhealtheconomicanalyses:im⁃plicationsofutilizingtheQHES[J].Jmanagcarepharm,2003,9(1):53-61.DrummondMF,JeffersonTO.GuidelinesforauthorsandpeerreviewersofeconomicsubmissionstotheBMJeconomicevaluationworkingparty[J].BMJ,1996,313(7052):275-283.EversS,GoossensM,DeVetH,etal.Criterialistforassessmentofmethodologicalqualityofeconomicevaluations:Con⁃sensusonhealtheconomiccriteria[J].IntJTechnolAssessHealthCare,2005,21(2):240-245.PhilipsZ,BojkeL,SculpherM,etal.Goodpracticeguide⁃linesfordecision-an